Can I read Neuroprotective Effect of Trans -Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial on EtoBox?

Neuroprotective Effect of Trans -Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial by Jiachen Gu; Zongshan Li; Huimin Chen; Xiaomin Xu; Yongang Li; Yaxing Gui is a Medicine article available to read on EtoBox.

What is Neuroprotective Effect of Trans -Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial about?

## Introduction Amyloid-beta (Aβ) protein is a major component of the extracellular plaque found in the brains of individuals with Alzheimer's disease (AD). In this study, we investigated the effect of __trans__-resveratrol as an antagonist treatment for moderate to mild AD, as well as its safety and tolerability. ## Methods This was a case–control study that enrolled 30 selected patients who had been clinically diagnosed with moderate to mild AD. These patients were randomly divided into two groups, namely, a placebo group (__n__ = 15) and a __trans__-resveratrol group (__n__ = 15) who received 500 mg __trans__-resveratrol orally once daily for 52 weeks. Brain magnetic resonance imaging (MRI) examinations were performed on and cerebrospinal fluid (CSF) samples were obtained from all participants before (baseline) and after the study (52 weeks). Enzyme-linked immunosorbent assays were used to determine the levels of plasma Aβ40 and Aβ42 and CSF Aβ40 and Aβ42. ## Results The results showed that the changes over the study period in the levels of Aβ40 in the blood and CSF of the patients treated with __trans__-resveratrol were not statistically significant (__P__ > 0.05). In contrast,

Who reads Neuroprotective Effect of Trans -Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial?

Author

Jiachen Gu; Zongshan Li; Huimin Chen; Xiaomin Xu; Yongang Li; Yaxing Gui

Publisher

Springer Science and Business Media LLC

Published

2021

Language

EN

Field

Medicine (Health Sciences)